Theralink Technologies, Inc. (THER)
| Previous close | 0.0007 |
| Open | 0.0007 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0007 - 0.0008 |
| 52-week range | 0.0007 - 0.0044 |
| Volume | |
| Avg. volume | 2,058,854 |
| Market cap | 4.921M |
| Beta (5Y monthly) | 20.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings date | 08 May 2024 - 21 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireTheralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
Golden, Colorado & Nashville, Tennessee, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (OTC: THER), a precision oncology company with an exclusively licensed commercial RPPA (reverse phase protein array) technology platform, is excited to announce groundbreaking work by George Mason University and the University of California, San Francisco, recently published in Cell Reports Medicine (https://linkinghub.elsevier.com/retrieve/pii/S2666379123005062). This incredible effort coming from
- GlobeNewswire
Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
Golden, Colorado & Nashville, Tennessee, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today with its merger partner, IMAC Holdings, INC (Nasdaq: BACK), announce that the companies have responded to the SEC’s first round of comments on the jointly filed form S-4. A Form S-4 i
- GlobeNewswire
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board
Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today announced that their long-standing, strategic partnership with the Inova Schar Cancer Institute (Inova) is beginning to deliver promising results by way of assessing the feasibility and impact of the action
